Lupin gets approval for Rufinamide Oral Suspension

21 Dec 2020 Evaluate

Lupin has received approval for its Rufinamide Oral Suspension, 40 mg/ml, from the United States Food and Drug Administration, to market a generic equivalent of Banzel Oral Suspension, 40 mg/ml, of Eisai Inc.

Rufinamide Oral Suspension, 40 mg/ml is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

1601.00 -4.35 (-0.27%)
14-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.